The study emphasises on the role of the p53 tumor suppressor gene in the pathogenesis of ulcerative colitis - an inflammatory bowel disease.

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

Results provide a mechanistic explanation of why early loss of p53 signaling is frequently observed in UC-associated ...

The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.

New research highlights a pivotal role for the p53 gene in ulcerative colitis progression, offering a potential therapeutic ...

Celltrion USA today announced a late-breaking post hoc analysis of the pivotal LIBERTY studies of ZYMFENTRA®, during the ...

US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with ...

Abdominal pain, diarrhea, and debilitating fatigue define the daily lives of millions of people worldwide who suffer from ...

Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated ...

DRB1*01:03 allele was significantly associated with increased severity of ulcerative colitis, including higher rates of ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

ALTB-268 demonstrated its anti-inflammatory effect in an acute colitis hPSGL-1 mouse model.The data confirmed that ALTB-268 acts as an immune ...